Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Govind Ragupathi(Memorial Sloan Kettering Cancer Center), Wen Jen Hwu(Memorial Sloan Kettering Cancer Center), Jedd D. Wolchok(Cornell University), John Gathuru(Memorial Sloan Kettering Cancer Center), Philip O. Livingston(Memorial Sloan Kettering Cancer Center), Chandra Hood(Memorial Sloan Kettering Cancer Center), Linda Williams(Edinburgh Cancer Research), Paul B. Chapman(Memorial Sloan Kettering Cancer Center), Roberta C. Oldfield(Memorial Sloan Kettering Cancer Center), Susan E. Krown(Memorial Sloan Kettering Cancer Center)
PubMed
November 1, 2003
Cited by 103
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k